New Delhi, Dec. 12 -- The Delhi High Court's division bench on Friday declined to stay a single-judge order that allows Indian drugmaker Dr Reddy's Laboratories to domestically manufacture and export semaglutide, the blockbuster weight-loss and diabetes drug, to countries where it is not under patent protection.

The higher bench refused interim relief to Novo Nordisk, which had sought to block Dr Reddy's from manufacturing and exporting the drug.

While denying interim relief, the bench issued notice on Novo's appeal and listed the matter for final disposal in the second week of January, likely on 15 January. A bench of Justice C. Hari Shankar and Justice Om Prakash Shukla said it was not inclined to interfere at this stage after hearing...